News | Antiplatelet and Anticoagulation Therapies | June 27, 2018

AFib Patients Want More Information About Anticoagulation Reversal

Majority of patients in five-country poll considered it important to know about a medication which could stop the blood thinning effects of their medication if needed

AFib Patients Want More Information About Anticoagulation Reversal

June 27, 2018 — Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance of patient-physician discussion around the reversal of blood thinning (anticoagulant) treatments in potential emergency situations.

AF is the most common cardiac rhythm disorder worldwide1 and increases the risk of stroke five-fold.2 Anticoagulants reduce the blood’s ability to form clots and reduce the risk of stroke. However, in emergency situations, such as when rapid initiation of surgery is required, or in the case of a life-threatening bleed, quick reversal of anticoagulation may be required.

AF patients in the survey were very aware of potential complications related to their treatment in the event of an emergency (89 percent).3 However, more than half (51 percent) could not recall having a discussion with their doctor about stopping their blood thinning medication in an emergency. Yet 78 percent would prefer such information about reversibility to come directly from their treating physician compared to other possible sources.

“First of all, it is important that AF patients understand the importance of anticoagulation and its role in preventing strokes. However, it is clear from these survey results that knowing more about how anticoagulant medication could be stopped in the event of an emergency is also very important to patients. This highlights the need for physicians to address this topic in ongoing discussions with their AF patients,” commented Prof. Harald Darius, head of the department of cardiology, angiology, nephrology and intensive-care medicine at the Vivantes Neukoelln Medical Center, Berlin in Germany.

Highlights from the survey include:

  • Sixty-four percent of patients surveyed said it would give them ‘peace of mind, allowing them to worry less about their health’ if they knew that the effects of their blood thinning medication could be reversed in case of an emergency;
  • Nearly 1 in 4 (23 percent) indicated they would feel ‘confident’ if they knew that there was a medication available that could stop the blood thinning effects of their anticoagulant treatment in case of an emergency; and
  • Thirty-one percent said it would allow them to live a more active lifestyle.

An online poll was conducted by Branding Science, an independent market research consultancy, on behalf of Boehringer Ingelheim. The poll was conducted in five countries between October and November 2017 amongst patients diagnosed with AF who have been prescribed a blood thinning (anticoagulation) therapy for stroke prevention.

The poll sought to evaluate patient attitudes towards anticoagulation and potential reversal in an emergency. It was conducted among 902 AF patients living in Belgium, Germany, Italy, Russia and the United States. The respondents were 63 percent male and 37 percent female, with 39 percent of the patients between 56 and 70 years of age being on blood thinning treatment because of AF for 6.8 years on average.

View the full survey results here.

For more information: www.boehringer-ingelheim.com

References

1. Lloyd-Jones DM, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-6.

2. Camm AJ, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart. 2012; 33:2719-2747

3. Research carried out by Branding Science, Data on file


Related Content

News | Antiplatelet and Anticoagulation Therapies

August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...

Home August 28, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

March 24, 2023 — According to the U.S. Food and Drug Administration (FDA), Ascend Laboratories LLC is voluntarily ...

Home March 24, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
Subscribe Now